These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8315429)

  • 1. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.
    Thompson DS; Hainsworth JD; Hande KR; Holzmer MC; Greco FA
    J Clin Oncol; 1993 Jul; 11(7):1322-8. PubMed ID: 8315429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study.
    Thompson DS; Hainsworth JD; Hande KR; Holzmer M; Greco FA
    Cancer; 1994 Jun; 73(11):2824-31. PubMed ID: 8194024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
    Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
    J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
    Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
    J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
    Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
    Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
    Minami H; Shimokata K; Saka H; Saito H; Ando Y; Senda K; Nomura F; Sakai S
    J Clin Oncol; 1993 Aug; 11(8):1602-8. PubMed ID: 8336196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
    Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
    J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies.
    Hainsworth JD; Utley SM; Greco FA
    Invest New Drugs; 1997; 15(4):325-9. PubMed ID: 9547675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer.
    Soni N; Meropol NJ; Pendyala L; Noel D; Schacter LP; Gunton KE; Creaven PJ
    J Clin Oncol; 1997 Feb; 15(2):766-72. PubMed ID: 9053503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
    Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
    Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.
    Sparano JA; Wiernik PH; Leaf A; Dutcher JP
    J Clin Oncol; 1993 Jun; 11(6):1071-9. PubMed ID: 8501493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
    Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
    Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.